19th July 2010
Cara Therapeutics Secures $15 million Series D Financing to Continue Clinical Development of CR845
Cara Therapeutics, Inc. announces the close of its Series D financing of $15 million
Read this article
3rd June 2010
PregLem Announces Additional Positive Phase III Results for Esmya
PregLem, a biopharmaceutical company focused on women’s reproductive medicine, announces positive Phase III data from its second pivotal study for Esmya (TM)
Read this article
18th May 2010
PregLem Announces Positive Phase III Results for Esmya as an Effective Treatment for Uterine Fibroids
PregLem, a biopharmaceutical company focused on women’s reproductive medicine, announces positive Phase III results of Esmya(TM)
Read this article
10th March 2010
Cheetah Medical Closes $20 million Series B Financing
Cheetah Medical, Inc., a worldwide leader in noninvasive haemodynamic and cardiac output monitoring technology, announces the closing of a $20 million financing round
Read this article
2nd February 2010
Vantia Therapeutics' Lead Candidate VA106483 enters Phase IIb Trial for Nocturia
Vantia Therapeutics, an emerging pharmaceutical company developing novel, small molecule drugs, today announces it has begun its planned Phase IIb trial of its lead development compound VA106483 for nocturia
Read this article
News Archive
Last 5 Articles | Next 5 Articles
11th November 2009MVM Fund III commits $5m to BioVex
BioVex (based in Woburn, MA, USA and Oxford, UK) is developing a high technology treatment “OncoVex” for metastatic melanoma. Melanoma is the most dangerous form of skin cancer and at present there is no effective treatment for its advanced, metastatic, form.
The current Series G round of financing of $30m is being led by external investors MVM, Morningside and Ventech. It follows a $40m Series F round completed in March by existing investors including Forbion and New Science Ventures.
OncoVex is currently being tested in a 360 patient Phase III trial which it is hoped will provide sufficient data for marketing approval by the FDA. OncoVex has also generated promising clinical data in other cancers.
The trial follows a Phase II trial in which 20% of treated patients showed complete and durable tumour clearance and 28% showed tumour shrinkage of over 30%.
OncoVex is a genetically engineered virus which is thought to benefit from a unique dual mechanism of action: the virus directly kill cells in injected tumours and stimulates a broader immune response against tumour cells through the body.
Dr Stephen Reeders will join the board of BioVex.
| Associated Links Visit BioVex |
Downloads Full Press Release |